Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

616
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
616
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.9K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.9K
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

992
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
992
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

1.1K
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.1K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

757
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
757
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

598
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
598

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "The current situation of intensive care units in Chinese mainland: A nationwide survey" [Journal of Intensive Medicine volume 2 (2026) 132-140].

Journal of intensive medicine·2026
Same author

Video-Based Training on Physicians' Proficiency in Invasive Fungal Disease: A Multicentre, Cluster Randomised Controlled Trial.

Mycoses·2026
Same author

Corrigendum to "Seeing Artery and VEin Simultaneously in the long axis (SAVES) for ultrasound-guided infraclavicular axillary/subclavian vein cannulation: A retrospective analysis" [Journal of Intensive Medicine volume 4 (2025) 350-358.].

Journal of intensive medicine·2026
Same author

Practice guideline on the prevention and treatment of central line-associated bloodstream infection: Part 2 - Treatment.

Journal of intensive medicine·2026
Same author

The current situation of intensive care units in Chinese mainland: A nationwide survey.

Journal of intensive medicine·2026
Same author

Practice guideline on the prevention and treatment of central line-associated bloodstream infection: Part 1--Diagnosis and prevention.

Journal of intensive medicine·2026

Related Experiment Video

Updated: Mar 20, 2026

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

7.7K

Efficacy and safety of ilaprazole for stress ulcer - associated upper gastrointestinal bleeding prophylaxis in

Jiao Liu1, Xiaojun Pan1, Sisi Huang1

  • 1Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin 2nd Road, Shanghai 200025, China.

Annals of Intensive Care
|March 19, 2026
PubMed
Summary
This summary is machine-generated.

Ilaprazole is non-inferior to esomeprazole in preventing upper gastrointestinal bleeding in critically ill patients. This randomized trial found similar efficacy and safety, with fewer hepatobiliary events for Ilaprazole.

Keywords:
EfficacyIlaprazoleSafetyStress ulcerUpper gastrointestinal bleeding

More Related Videos

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt
12:27

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt

Published on: May 7, 2015

17.0K

Related Experiment Videos

Last Updated: Mar 20, 2026

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

7.7K
Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt
12:27

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt

Published on: May 7, 2015

17.0K

Area of Science:

  • Critical Care Medicine
  • Gastroenterology
  • Pharmacology

Background:

  • Critically ill patients are at high risk for stress ulcer-associated upper gastrointestinal bleeding (UGIB).
  • Proton pump inhibitors (PPIs) are standard prophylaxis, but efficacy and safety profiles vary.
  • Ilaprazole is a novel PPI investigated for UGIB prevention.

Purpose of the Study:

  • To evaluate the non-inferiority of Ilaprazole compared to esomeprazole in preventing stress ulcer-associated UGIB.
  • To assess the safety and tolerability of Ilaprazole in this patient population.

Main Methods:

  • A randomized, double-blind, non-inferiority Phase 3 trial conducted in 70 hospitals across China.
  • 441 high-risk critically ill patients requiring mechanical ventilation were enrolled.
  • Patients received either Ilaprazole (10 mg daily, double first dose) or esomeprazole (40 mg twice daily).

Main Results:

  • Ilaprazole demonstrated non-inferiority to esomeprazole, with primary endpoint event rates of 96.80% vs. 97.30% (Absolute Risk Difference: -0.47, 95% CI: -4.02, 3.03).
  • Comparable incidences of clinically insignificant UGIB, overall GI bleeding, 28-day mortality, ICU mortality, and pneumonitis were observed.
  • Ilaprazole showed a significantly lower incidence of hepatobiliary disorders (0.9% vs. 5%, p = 0.012).

Conclusions:

  • Ilaprazole is a safe and effective alternative to esomeprazole for preventing UGIB in critically ill patients.
  • The study supports Ilaprazole's use in preventing stress ulcer-associated bleeding in high-risk populations.
  • Ilaprazole's favorable safety profile regarding hepatobiliary disorders warrants further attention.